Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Quest Diagnostics CEO and President J. E. Davis reported two stock transactions in company common stock. He disposed of 2,968 shares at $204.86 per share to satisfy tax obligations from the vesting of a prior restricted share unit grant. He also completed an open-market sale of 10,000 shares at $212.52 per share under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 117,185 Quest Diagnostics shares.

Insider Trade Summary

Net Seller: 10,000 shares ($2,125,200)

Net Sell 2 txns

Insider Davis J. E.

Role CEO and President

Sold 10,000 shs ($2.13M)

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,968	$204.86	$608K
Sale	Common Stock	10,000	$212.52	$2.13M

Holdings After Transaction: Common Stock — 127,185 shares (Direct)

Footnotes (1)

Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

03/04/2026 - 04:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis J. E.

(Last)

(First)

(Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS

07094

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		F		2,968⁽¹⁾	D	$204.86	127,185	D
Common Stock	03/02/2026		S⁽²⁾		10,000	D	$212.52	117,185	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.

2. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for James E. Davis	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions did Quest Diagnostics (DGX) CEO report?

Quest Diagnostics CEO J. E. Davis reported two transactions in common stock. He disposed of 2,968 shares to cover taxes from restricted share units and sold 10,000 shares in an open-market transaction under a Rule 10b5-1 sales plan.

How many Quest Diagnostics (DGX) shares did the CEO sell and at what prices?

J. E. Davis reported a tax-related disposition of 2,968 Quest Diagnostics shares at $204.86 per share. He also executed a separate open-market sale of 10,000 shares at $212.52 per share as part of his disclosed trading activity.

Were the Quest Diagnostics (DGX) CEO’s stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the reported open-market sale was effected under a Rule 10b5-1 sales plan adopted by J. E. Davis. Such plans pre-schedule trades, aiming to separate personal trading decisions from nonpublic company information.

Why did the Quest Diagnostics (DGX) CEO dispose of 2,968 shares?

The 2,968 Quest Diagnostics shares were sold to satisfy tax obligations from the vesting of a previous restricted share unit grant. This type of transaction is commonly used so executives can cover withholding taxes without paying cash out of pocket.

How many Quest Diagnostics (DGX) shares does the CEO hold after these transactions?

After completing the tax-related disposition and the open-market sale, J. E. Davis directly holds 117,185 Quest Diagnostics common shares. This total reflects his remaining direct ownership following the combined 12,968-share reduction disclosed in the filing.

What do transaction codes F and S mean in the Quest Diagnostics (DGX) CEO filing?

Code F indicates shares withheld or sold to pay taxes from equity awards, here 2,968 shares for restricted share units. Code S reflects a sale in the open market or private transaction, applied to the 10,000-share open-market sale at $212.52 per share.